Fidelity Investments
ACHN

Fidelity Investments’s Achillion Pharmaceuticals ACHN Stock Holding History

Fidelity Investments’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-74
Closed – – 4424
2019
Q2 		$0 Buy
+74
New +$219 ﹤0.01% 4372
2019
Q1 		– Sell
-1,000
Closed -$2K – 4446
2018
Q4 		$2K Buy
+1,000
New +$2.83K ﹤0.01% 3363
2018
Q2 		– Sell
-1,450,481
Closed -$5.38M – 2767
2018
Q1 		$5.38M Sell
1,450,481
-683
-0% -$2.23K ﹤0.01% 2139
2017
Q4 		$4.18M Buy
1,451,164
+683
+0% +$2.48K ﹤0.01% 2207
2017
Q3 		$6.51M Sell
1,450,481
-153,141
-10% -$680K ﹤0.01% 2089
2017
Q2 		$7.36M Buy
1,603,622
+159,218
+11% +$640K ﹤0.01% 2052
2017
Q1 		$6.08M Sell
1,444,404
-76,800
-5% -$319K ﹤0.01% 2128
2016
Q4 		$6.28M Sell
1,521,204
-1,779,867
-54% -$9.46M ﹤0.01% 2122
2016
Q3 		$26.7M Sell
3,301,071
-4,403,335
-57% -$37.4M ﹤0.01% 1550
2016
Q2 		$60.1M Sell
7,704,406
-349,466
-4% -$3M 0.01% 1191
2016
Q1 		$62.2M Sell
8,053,872
-816,100
-9% -$5.98M 0.01% 1156
2015
Q4 		$95.7M Hold
8,869,972
– – 0.01% 983
2015
Q3 		$61.3M Hold
8,869,972
– – 0.01% 1155
2015
Q2 		$78.6M Hold
8,869,972
– – 0.01% 1138
2015
Q1 		$87.5M Sell
8,869,972
-1,963,844
-18% -$24.5M 0.01% 1084
2014
Q4 		$133M Buy
10,833,816
+4,309,244
+66% +$52.6M 0.02% 866
2014
Q3 		$65.1M Sell
6,524,572
-39,200
-0.6% -$364K 0.01% 1177
2014
Q2 		$49.7M Buy
6,563,772
+5,678,572
+642% +$22.7M 0.01% 1338
2014
Q1 		$2.91M Buy
885,200
+530,275
+149% +$1.86M ﹤0.01% 2306
2013
Q4 		$1.18M Sell
354,925
-5,744,132
-94% -$16.7M ﹤0.01% 2428
2013
Q3 		$18.4M Sell
6,099,057
-5,102,325
-46% -$35M ﹤0.01% 1721
2013
Q2 		$91.6M Buy
+11,201,382
New +$85.5M 0.02% 956

Other funds holding ACHN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Fidelity Investments's ACHN Position: Q3 2019 in Review

Fidelity Investments sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 74 shares.

Fidelity Investments first reported a position in ACHN in Q2 2013 and held it in 22 quarters. The position peaked at $133M in Q4 2014. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

  • Fidelity Investments reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fidelity Investments sold 74 Achillion Pharmaceuticals shares in Q3 2019.
  • Fidelity Investments first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Fidelity Investments's Achillion Pharmaceuticals position peaked at $133M in Q4 2014.
  • 122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Fidelity Investments's 13F filing for Q3 2019, filed 13 Nov 2019.